Navidea Biopharmaceuticals (NAVB) Financials

$0.00

$-0.04 (-99.76%)

As on 18-Dec-2025 09:30EDT

Market cap

$0 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

8.2

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Operating Revenue	0.00	0.07	0.53	0.92	0.03	0.32
Cost of Revenue	0.16	0.18	0.20	0.00	0.01	0.10
Gross Profit	-0.16	-0.12	0.33	0.91	0.02	0.23
Operating Expenses	10.13	13.93	12.39	11.63	10.98	11.07
Operating Profit (EBIT)	-10.18	-14.05	-12.06	-10.71	-10.96	-10.85
Other Income	--	--	--	-0.01	0.02	-5.29
Profit before Tax	-8.61	-15.18	-11.71	-10.72	-10.94	-16.17
Provision for Tax	-7.15	2.04	0.02	-0.08	0.00	0.00
Profit after Tax (Net Income)	-1.18	-17.22	-11.73	-10.64	-10.95	-16.13
Minority Interest	0.00	0.00	0.00	0.73	0.00	0.00
Consolidated Profit	8.17	-17.22	-11.73	-11.39	-10.95	-16.11

Liabilities ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Shareholder's Funds	-3.27	-8.44	-0.11	1.32	-1.61	1.73
Minority Interest	0.00	--	--	0.73	0.73	0.67
Non-Current Liabilities	0.70	2.57	0.72	1.00	1.21	1.23
Current Liabilities	7.98	9.94	5.30	4.72	3.82	3.38
Total Liabilities	13.68	4.37	6.64	7.76	4.15	7.01

Assets ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Non-Current Assets	1.20	1.17	1.26	1.23	1.24	2.03
Current Assets	4.50	3.20	5.38	6.53	2.92	4.97
Total Assets	13.68	4.37	6.64	7.76	4.15	7.01
Total Debt*	1.26	2.44	0.75	1.34	1.07	0.32
Net Current Assets	-3.48	-6.74	0.08	1.81	-0.90	2.22

Cashflow ($ Mln)	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Cash From Operating Activities	--	-8.99	-10.22	-8.17	-9.35	4.28
Cash Flow from Investing Activities	--	-0.39	-0.33	-0.41	0.77	0.95
Cash from Financing Activities	--	7.14	12.11	10.21	6.16	-4.55
Net Cash Inflow / Outflow	--	--	--	1.62	-2.43	0.68

Financials Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Adjusted EPS ($)	-0.05	-0.53	-0.39	-0.40	-0.60	-1.70
Cash EPS ($)	--	-0.53	-0.39	-0.40	-0.59	-1.68
Adjusted Book Value ($)	--	--	--	0.05	--	0.18
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-0.28	-0.34	-0.31	-0.51	0.45
Free Cash Flow per Share ($)	--	-0.29	-0.35	-0.32	-0.51	0.45

Profitability Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
ROCE (%)	--	642.67	-712.07	-1,009.21	-1,457.20	-204.40
ROE (%)	--	403.05	-1,940.52	7,172.49	-18,655.01	-246.03
ROA (%)	-8.34	-312.53	-162.90	-178.69	-196.16	-116.06
EBIT Margin (%)	-1,476,651.48	-21,402.08	-2,202.30	-1,170.60	-41,184.60	-3,409.91
Net Margin (%)	-193,849.18	-26,221.65	-2,207.08	-1,176.33	-24,711.69	324.61
Cash Profit Margin (%)	-1.79	--	--	--	--	--

Growth Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Revenue Growth (%)	-99.05	-0.88	-0.42	33.38	-0.92	-0.82
EBIT Growth (%)	40.99	-20.04	-9.28	2.29	0.32	17.92
Net Profit Growth (%)	92.30	-46.75	-10.25	2.79	32.13	-121.52
EPS Growth (%)	90.01	-0.37	0.02	0.33	0.65	-1.19
Book Value Growth (%)	79.59	--	--	--	--	--

Valuation Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Price / Earnings	--	-0.39	-2.57	-5.40	-2.10	-0.06
Price / Book Value	8.16	-0.81	-283.06	43.67	-14.29	0.56
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-0.54	-0.52	-2.32	-5.27	-2.13	0.28
Close Price ($)	0.09	0.21	1.00	2.15	1.26	2.05
High Price ($)	0.35	1.27	3.15	5.36	4.20	8.48
Low Price ($)	0.06	0.16	0.93	0.63	0.49	2.01
Market Cap ($ Cr)	0.01	--	--	--	--	--

Solvency Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Debt to Equity	--	-0.29	-7.03	1.02	-0.66	0.18
Short term debt to equity ratio	-0.38	-0.07	-6.84	0.79	-0.50	0.18
Current Ratio	0.56	0.32	1.02	1.38	0.76	1.47
Quick Ratio	0.51	0.28	0.99	1.35	1.00	1.47
Interest Coverage	-6.02	-12.79	-1,840.20	-944.22	-433.51	-357.08

Operating Efficiency Ratios	TTM	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13
Debtors to sales (%)	5,060.66	0.96	17.50	326.48	3,386.20	6.56
Asset Turnover	0.00	0.01	0.07	0.15	0.00	0.02
Receivable days	--	260.43	1,058.38	776.13	6,329.17	4,619.98
Inventory Days	--	571.24	294.79	-127,478.70	-24,689.79	0.00
Payable days	--	3,499.36	2,372.46	396,231.08	42,096.25	2,418.52
Cash Conversion Cycle	--	-2,667.70	-1,019.30	-522,933.65	-60,456.88	2,201.46

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.